Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain

This study has been terminated.
(Safety considerations)
Sponsor:
Information provided by (Responsible Party):
Dr David Langleben, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT01433328
First received: September 9, 2011
Last updated: April 4, 2012
Last verified: April 2012
  Purpose

Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients. The investigators plan to treat patients receiving treprostinil with a subcutaneous infusion of lidocaine (a local anesthestic) to treat the pain.


Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: Lidocaine
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Resource links provided by NLM:


Further study details as provided by Jewish General Hospital:

Primary Outcome Measures:
  • Pain Questionnaire [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
    Short Form McGill Pain Questionnaire - Change from baseline over one week

  • Daily Pain Diary [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
    10cm visual analogue scale (VAS) - Change in aggregated median/maximum scores over one week


Secondary Outcome Measures:
  • proNT-BNP [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
  • 6 minute walk [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
  • Lidocaine level [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]

Enrollment: 4
Study Start Date: January 2012
Study Completion Date: April 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lidocaine Drug: Lidocaine
Lidocaine
Placebo Comparator: Placebo
Remodulin only
Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PAH
  • Treprostinil treatment for at least 3 months
  • Severe infusion site pain

Exclusion Criteria:

  • Pregnancy/breastfeeding
  • Decompensated heart failure
  • Chronic liver disease
  • Abnormal electrolytes
  • Heart block (2/3 degree), sino-atrial block, idioventricular rhythm
  • Systolic systemic BP <90mmHg
  • Bradycardia HR <55
  • Adverse reaction to lidocaine or other amide local anesthestic
  • Interacting medications (anti-arrhythmics, CYP1A2 inhibitors)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01433328

Locations
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Jewish General Hospital
Investigators
Principal Investigator: David Langleben, MD Chair, Cardiology Department
  More Information

No publications provided

Responsible Party: Dr David Langleben, Chair, Cardiology Department, Jewish General Hospital
ClinicalTrials.gov Identifier: NCT01433328     History of Changes
Other Study ID Numbers: JGH-11-096
Study First Received: September 9, 2011
Last Updated: April 4, 2012
Health Authority: Canada: Health Canada

Keywords provided by Jewish General Hospital:
Remodulin
Treprostinil

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Lidocaine
Treprostinil
Anesthetics
Anesthetics, Local
Anti-Arrhythmia Agents
Antihypertensive Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers

ClinicalTrials.gov processed this record on November 27, 2014